Answers are grounded in this paper and cite their sources.
Background and Purpose: Biologics are crucial for severe asthma treatment, but their high costs pose challenges. Omalizumab (OML) is dosed on the basis of patient-specific factors. The purpose of this study is to clarify the clinical characteristics of severe asthmatics who maintain long-term control on omalizumab including healthcare cost considerations. Patients and Methods: A retrospective, multicenter cohort study was conducted. Patients receiving OML at three institutions were enrolled. Patients continuing OML (C-OML) were compared with those switching to other biologics (S-OML) in terms of clinical background, cost-effectiveness, and type-2 inflammation levels. Results: Forty-seven patients were enrolled. The C-OML group achieved exacerbation control comparable to that of the S-OML group, with a median OML dose of 300 mg/month, resulting in significantly lower personal payments ( p < 0.01). Compared with the S-OML group, the C-OML group had a greater prevalence of overweight ( p = 0.04), a lower prevalence of eosinophilic chronic rhinosinusitis ( p < 0.01), and a trend toward a higher prevalence of allergic rhinitis ( p = 0.06). Effective asthma control with OML was associated with nonsevere type-2 inflammation (eosinophils < 300/μL and FeNO < 50 ppb). Conclusion: Patients with nonsevere type-2 inflammation and a high BMI can achieve effective asthma control with OML, reducing treatment costs. Identifying this phenotype can improve the cost-effectiveness of biologic therapies for patients with severe asthma. Plain Language Summary: Biologic treatments are important for managing severe asthma, but they can be expensive. Patients who maintained long-term control with omalizumab had significantly lower biologic-related healthcare costs compared to those who switched therapies. They were characterized by nonsevere type 2 inflammation, elevated BMI, allergic rhinitis, and absence of ECRS. Understanding a patient’s background is crucial when choosing the most appropriate treatment option.
No takes yet. Share an insight, caveat, or question.
Sunadome et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: